Sudarshan Pharma Industries Ltd has provided a comprehensive update on the GST inspection, search and seizure operation that concluded successfully on February 25, 2026. The operation, which commenced at its registered office on February 21, 2026, was conducted by the Goods & Service Tax Department, Mumbai, Maharashtra.

Official Communication and Updated Disclosure

Sudarshan Pharma Industries made the updated disclosure through official communication dated February 26, 2026, addressed to BSE Limited under reference number SPIL/CS/SE/2025-2026/74. This follows the initial notification made on February 22, 2026, demonstrating the company's commitment to continuous transparency and regulatory compliance under SEBI Listing Obligations.

Inspection Timeline and Conclusion

The GST inspection operation spanned five days, from February 21, 2026 to February 25, 2026. Throughout this period, company officers provided full cooperation to GST Department officials, supplying all necessary documents, information, and clarifications as requested by the authorities.

Key Findings and Compliance Status

The inspection results revealed favorable outcomes for Sudarshan Pharma Industries. According to the detailed annexure provided under SEBI circular requirements, no violations or contraventions were found attributable to the company's compliance and filings. Any liability identified was related to non-compliance by a vendor of the company, not the company's own operations.

Regulatory Framework and Authorization

Chairman & Managing Director Hemal Mehta signed the updated communication, replacing the earlier signatory Company Secretary Nirav Shah. The disclosure was made in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, which requires detailed reporting of regulatory actions.

The successful conclusion of the GST inspection with no material findings against the company reinforces Sudarshan Pharma Industries' strong compliance framework and operational integrity, providing reassurance to investors and stakeholders about the company's regulatory standing.

Sudarshan Pharma Industries Limited has announced the successful obtainment of two critical certifications for its API manufacturing facility, marking a significant milestone in the company's quality assurance journey. The certifications underscore the company's commitment to maintaining global quality benchmarks and robust manufacturing practices in the pharmaceutical sector.

Certification Details

The company has secured two important certifications for its manufacturing facility located at Plot No. D 22, TGIIC-IALA, IDA-Medchal, Medchal-Malkajgiri District, Hyderabad, Telangana - 501401:

Validity and Timeline

Both certifications carry significant validity periods, providing the company with long-term compliance assurance:

Strategic Significance

These certifications represent a crucial development for Sudarshan Pharma Industries Limited's manufacturing capabilities. The GMP certification ensures that the company's manufacturing processes meet international standards for pharmaceutical production, while the ISO 9001:2015 certification validates the company's quality management systems.

The certifications cover the manufacturing of API intermediates and Active Pharmaceutical Ingredients, which are critical components in pharmaceutical production. This achievement positions the company as a reliable and compliant manufacturer in the competitive API and pharmaceutical intermediates segment.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent communication with stakeholders. The certifications are subject to satisfactory surveillance audits to maintain their validity throughout the certification period.

These quality certifications are expected to enhance the company's credibility with existing and potential clients, particularly in international markets where GMP and ISO certifications are often mandatory requirements for pharmaceutical suppliers.